SCM
MDGL icon

Superstring Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Superstring Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,815
Closed -$1.26M – 41
2025
Q1 		$1.26M Buy
3,815
+2,686
+238% +$883K 1.5% 20
2024
Q4 		$348K Buy
+1,129
New +$318K 0.3% 36

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Superstring Capital Management's MDGL Position: Q2 2025 in Review

Superstring Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2025, closing a stake of 3,815 shares — an estimated $1.26M sold.

Superstring Capital Management first reported a position in MDGL in Q4 2024 and held it in 2 quarters. The position peaked at $1.26M in Q1 2025. 305 funds tracked by Wall St. Rank hold MDGL as of Q2 2025.

  • Superstring Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Superstring Capital Management sold 3,815 Madrigal Pharmaceuticals shares in Q2 2025, an estimated $1.26M.
  • Superstring Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Superstring Capital Management's Madrigal Pharmaceuticals position peaked at $1.26M in Q1 2025.
  • 305 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2025.

Based on Superstring Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.